Medicare Drug Pricing Casts A Cloud Over J.P. Morgan’s Opening Day
Inflation Reduction Act means that industry ‘will have to adjust’ to new market realities, especially for small molecule drugs.
You may also be interested in...
Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans.
Merck & Co. CEO Rob Davis said the company is already factoring policy changes from the Inflation Reduction Act into its business development decisions.
Prospect of Medicare price setting under the Inflation Reduction Act was factored into the rationale for two recent and notable deals for products with limited exposure to the government insurance program.